PubMed Health⌕ Search

Biomedical subjects

P Tepmongkol

Publications and source records attributed to P Tepmongkol.

At least 19 recordsLinked to original sources
PubMed1997

Accuracy of apex locator.

An evaluation of the accuracy of the "Root ZX" apex locator was conducted on 20 single-rooted teeth that had been extracted because of severe disease or orthodontic treatment. After the pulp chamber had been accessed and the tooth length determined using the Root ZX apparatus, the file was fixed to the tooth with light-cured composite resin. After extraction, the tooth was longitudinally ground with a diamond bur until the file was visible. The distance between the file tip and the apical foramen was measured under a microscope (x 100). The results showed that the tip of the instrument reached the apical foramen in all teeth.

Adult↗
PubMed1991

Neoadjuvant carboplatin & 5 fluorouracil combination chemotherapy and radiotherapy in the treatment of locally advanced head and neck cancer: primary report.

We studied the effect of neoadjuvant carboplatin/5-FU combination chemotherapy and radiotherapy in the treatment of 53 patients with locally advanced head and neck cancer in Siriraj Hospital. Carboplatin 350-450 mg/m2 I.V. on day 1, and 5-FU 1,000 mg/m2/d on days 1-4, were administered either on an in- or out-patient basis. We obtained a response rate of 85 per cent, with 13 per cent complete response after 2-3 cycles of neoadjuvant chemotherapy. After the completion of subsequent radiotherapy, the response rate increased to 94 per cent, with 40 per cent CR. After the additional 2-3 cycles of postradiation chemotherapy, the final overall response rate was 96 per cent, with 77 per cent CR. Only 4 per cent of patients had grade 3 GI toxicity and 25 per cent of patients had grade 2, 3 myelosuppression. All patients tolerated the treatment very well. Long-term study for the duration time of response and survival are being collected.

Adult↗
PubMed1990

Megestrol acetate as the supportive treatment of Thai patients with advanced cancer.

We studied the effect of the standard oral dose (160 mg/d) of megestrol acetate on the weight gain of 115 advanced cancer patients. All were underweight and were receiving only supportive or symptomatic care. The median treatment time was 74 weeks (range: 4 weeks to 2 years). The mean body weight gain of all patients was 4.84 kg (range: -3 to 18 kg) regardless of the disease status. Weight gain was dependent on the length of treatment time. The performance status after therapy also shifted to the better status with significant statistical difference. All patients felt an increase of appetite and also had an improved sense of well-being. No serious side-effects of the treatment were noted in this study.

Adult↗
PubMed1989

Mitoxantrone as single agent in the treatment of advanced breast cancer: clinical experience at Siriraj Hospital.

A total of 35 patients with advanced breast cancer were treated with mitoxantrone, 14 mg/m2 I.V. every 3 weeks. Of these, 27 patients or 78 lesions could be evaluated for response and all 35 patients for toxicity. The overall response rate (CR + PR) was 35 per cent (or CR + PR + SD = 82%), ten lesions achieved a complete response and 17 lesions a partial response. The duration of response varied from a minimum of 2 months to more than 11 months (median = 4 months). Myelosuppression was the dose-limiting toxicity with moderate to severe degree in 19 patients. The most frequent severe degree in 19 patients. The most frequent non-hematologic toxicity was mild grade of nausea and vomiting (67%). No cardiotoxicity was noted in this study after the maximum cumulative dose of mitoxantrone 157.5 mg.

Adult↗